Metronidazole-loaded polydopamine nanomedicine with antioxidant and antibacterial bioactivity for periodontitis.
Nanomedicine (Lond)
; 18(29): 2143-2157, 2023 12.
Article
em En
| MEDLINE
| ID: mdl-38127626
ABSTRACT
Aim:
This study focused on treating periodontitis with bacterial infection and local over accumulation of reactive oxygen species. Materials &methods:
Polydopamine nanoparticles (PDA NPs) were exploited as efficient carriers for encapsulated metronidazole (MNZ). The therapeutic efficacy and biocompatibility of PDA@MNZ NPs were investigated through both in vitro and in vivo studies.Results:
The nanodrug PDA@MNZ NPs were successfully fabricated, with well-defined physicochemical characteristics. In vitro, the PDA@MNZ NPs effectively eliminated intracellular reactive oxygen species and inhibited the growth of Porphyromonas gingivalis. Moreover, the PDA@MNZ NPs exhibited synergistic therapy for periodontitisin in vivo.Conclusion:
PDA@MNZ NPs were confirmed with exceptional antimicrobial and antioxidant functions, offering a promising avenue for synergistic therapy in periodontitis.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Periodontite
/
Polímeros
/
Nanopartículas
/
Indóis
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article